A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer
Conditions
- Non Small Cell Lung Cancer
Interventions
- DRUG: Anlotinib Hydrochloride plus Docetaxel
Sponsor
Shandong Cancer Hospital and Institute
Collaborators